<?xml version="1.0" encoding="UTF-8"?>
<p id="p0055">On 5 November 2019, WHO issued a draft set of Target Product Profiles (TPPs) describing optimal and minimally acceptable targets for vaccines against Rift Valley fever (RVF) in both humans and ruminants (
 <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/articles-detail/rift-valley-fever-vaccines-target-product-profile" id="ir005" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.who.int/news-room/articles-detail/rift-valley-fever-vaccines-target-product-profile</ext-link>). RVF is on WHOâ€™s Blueprint list of priority diseases with epidemic potential for which there are no or insufficient, countermeasures available. As will be described below, currently there are approved and investigational RVF live, attenuated vaccines (LAVs) for veterinary use. Only one investigational RVF LAV has so far been tested in humans, but promising new LAVs are in preclinical development.
</p>
